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Background: ECBio has developed proprietary technology to consistently isolate, expand and cryopreserve a
well-characterized population of stromal cells from human umbilical cord tissue (UCX® cells). The technology has
recently been optimized in order to become compliant with Advanced Medicine Therapeutic Products. In this work
we report the immunosuppressive capacity of UCX® cells for treating induced autoimmune inflammatory arthritis.
Methods: UCX® cells were isolated using a proprietary method (PCT/IB2008/054067) that yields a well-defined
number of cells using a precise proportion between tissue digestion enzyme activity units, tissue mass, digestion
solution volume and void volume. The procedure includes three recovery steps to avoid non-conformities related
to cell recovery. UCX® surface markers were characterized by flow cytometry and UCX® capacity to expand in vitro
and to differentiate into adipocyte, chondrocyte and osteoblast-like cells was evaluated. Mixed Lymphocyte
Reaction (MLR) assays were performed to evaluate the effect of UCX® cells on T-cell activation and Treg conversion
assays were also performed in vitro. Furthermore, UCX® cells were administered in vivo in both a rat acute
carrageenan-induced arthritis model and rat chronic adjuvant induced arthritis model for arthritic inflammation.
UCX® anti-inflammatory activity was then monitored over time.
Results: UCX® cells stained positive for CD44, CD73, CD90 and CD105; and negative for CD14, CD19 CD31, CD34,
CD45 and HLA-DR; and were capable to differentiate into adipocyte, chondrocyte and osteoblast-like cells. UCX® cells
were shown to repress T-cell activation and promote the expansion of Tregs better than bone marrow mesenchymal
stem cells (BM-MSCs). Accordingly, xenogeneic UCX® administration in an acute carrageenan-induced arthritis model
showed that human UCX® cells can reduce paw edema in vivo more efficiently than BM-MSCs. Finally, in a chronic
adjuvant induced arthritis model, animals treated with intra-articular (i.a.) and intra-peritoneal (i.p.) infusions of UCX®
cells showed faster remission of local and systemic arthritic manifestations.
Conclusion: The results suggest that UCX® cells may be an effective and promising new approach for treating both
local and systemic manifestations of inflammatory arthritis.
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Many forms of inflammatory arthritis are autoimmune
disorders, in which the body identifies its own tissues as
foreign and reacts with inflammation. Autoimmune con-
ditions include Rheumatoid Arthritis, Lupus, Ankylosing
Spondylitis, Reiter’s Syndrome, Psoriatic Arthritis and
arthritis associated with Inflammatory Bowel Disease [1].
Rheumatoid arthritis (RA), for example, is an immuno-
logically mediated chronic and systemic disease where
synovial joints are attacked leading to articular destruction
and functional disability. The molecular defect causing
RA has not been characterized, but may involve aberrant
T-cell, B cell, and macrophage function. Although RA
often responds to immunosuppressive medication in-
cluding corticosteroids, methotrexate, azathioprine and
cyclophosphamide, or to non-steroidal anti-inflammatory
drugs, no therapy has been curative and often patients
become non-responsive to therapeutic drugs. More recent
efforts to discover new target therapies have achieved
some success in alleviating inflammation; for instance,
TNF-α blockers, like the monoclonal antibodies etanercept
(Enbrel), infliximab (Remicade), adalimumab (Humira),
certolizumab pegol (Cimzia) and golimumab (Simponi),
and B-Lymphocyte depleting therapies, like rituximab
(Rituxan), have benefited many RA patients [2,3]. How-
ever, these approaches are very expensive and none of the
currently widely used biological agents reaches long term
drug-free remission [4,5]. It is therefore important to
develop new and more effective therapies for auto-
immune-based inflammatory arthritis.
Mesenchymal stromal/stem cells (MSCs) display im-
munosuppressive and anti-inflammatory properties, and
their putative therapeutic role in a variety of inflam-
matory autoimmune diseases is currently under investiga-
tion [6-8]. An essential characteristic of MSCs is that they
express a variety of chemokine and cytokine receptors that
drive them to sites of inflammation [9-12]. Thus, the
immune-regulatory effects of MSCs occur in a localized
environment and are not systemic, unlike steroid therapy
where systemic suppression can lead to major clinical
complications [13]. MSCs derived from umbilical cord
tissue (UC-MSCs) have been specifically shown to be
viable for allogeneic applications due to both their low
immunogenicity, even when compared to MSCs from
other sources, and their capacity for localized immunosup-
pression. In fact, immunosuppression activity of UC-MSCs
is thought to be enhanced by inflammation signals and can
be induced in vitro by pro-inflammatory treatment with
IFN-γ or TNF-α [14,15]. More recently, UC-MSCs have
been shown to be capable of inhibiting proliferation of
fibroblast-like synoviocytes (FLSs), inducing hyporespon-
siveness of T-cells and promoting the expansion of regula-
tory T-cells (Tregs) from RA patients in vitro [12,16,17].
More importantly, systemic infusion of human UC-MSCsreduced the severity of collagen-induced arthritis (CIA) in
mouse models, through a mechanism involving down
regulation of pro-inflammatory cytokine and chemokine
levels [TNF-α, IL-6, monocyte chemoattractant protein-1,
D-dimer (D-D), antithrombin-III (AT-III), thrombomodu-
lin (TM)] and up regulation of the anti-inflammatory cyto-
kine IL-10, as measured in sera of UC-MSCs-treated mice
[16,17]. Overall, these results suggest that UC-MSCs might
be a therapeutic strategy in RA.
ECBio has developed proprietary technology to consist-
ently isolate, expand, and cryopreserve a well-characterized
population of human stem cells derived from the umbi-
lical cord tissue (Wharton’s jelly) named herein as UCX®
cells [18]. The method has been specifically designed for
clinical use. Briefly, the main distinguishing differences
between UCX® isolation technology and other UC-MSC
isolation methods described previously are (1) the intro-
duction of a three-stage strategy for cell recovery which
makes the method 100% reliable, (2) peeling off the am-
niotic membrane which reduces the frequency of micro-
bial contamination and augments the purity of the
resulting UCX® population by eliminating epithelial pro-
genitors, (3) absence of tissue incisions and/or tissue min-
cing/crushing steps that could hinder its application in
GMP settings and jeopardize stem cell phenotype due to
excessive mechanical manipulation [19-23], and (4) using
an optimized ratio between tissue mass, digestion enzyme
activity units, overall solution volume and void volume
which allows for UCX® cell-specific release, leaving cord
vessels intact and therefore reducing contamination with
endothelial and sub-endothelial cells from umbilical arte-
ries and vein. The overall avoidance of cell mechanical
manipulation is one of the major goals of regulatory
authorities, not only for phenotype maintenance but also
because the lack of complex incision steps will improve
reproducibility and subsequent risk assessment. More
recently, the method has been adapted according to
advanced therapy medicinal product (ATMP) standards,
as defined by the guideline on the minimum quality data
for certification of ATMP (EMA/CAT/486831/2008/corr,
2010). The aim now is to gather non-clinical evidence sup-
porting the application of the resulting UCX® cell popula-
tion for the treatment of inflammatory arthritis. In this
study, UCX® cells were isolated and expanded up to pas-
sage 5 (P5), and characterized in terms of expression of
cell-surface markers, tri-lineage differentiation, and the cap-
acity to suppress the activation of T-cells and induce Tregs
in vitro. Furthermore, UCX® cells were xenogeneically used
in both acute carrageenan-induced arthritis (CarrIA) and
chronic adjuvant-induced arthritis (AIA) models for arth-
ritic inflammation, and their anti-inflammatory action
monitored over time. The results suggest that the use of
UCX® cells may be an effective new approach for treating
both local and systemic manifestations of inflammatory
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promising therapeutic agents than bone marrow-derived
mesenchymal stem cells (BM-MSCs).Methods
Ethics and regulatory
This study was approved by the Ethics Committee at the
Cascais Hospital Dr. José de Almeida, in the scope of a
research protocol between ECBio – Research & Develop-
ment in Biotechnology, S.A. and HPP Saúde – Parcerias
Cascais, S.A. Umbilical cord donations (n = 8) proceeded
with written informed consents according to Directive
2004/23/EC which sets the standards of quality and safety
for the donation, procurement, testing, processing, preser-
vation, storage and distribution of human tissues and cells.
All the experimental procedures were carried out with the
permission of the local laboratory animal research commit-
tees in accordance with internationally accepted guidelines,
especially taking in consideration the 3Rs rule of -
Replacement, Refinement and Reduction. All animals
were obtained from Charles River Laboratories (Santa
Perpetua de Mogoda, Spain) and kept under standard
laboratory conditions. All animals were acclimatized
before the experiments and housed in plastic cages under
standard laboratory conditions, fed commercial chow and
acidified drinking water ad libitum.UCX® isolation and cryopreservation
Human UCX® cells were isolated according to Santos et al.
(2008). Briefly, fresh human umbilical cords were
obtained after full-term natural births, transported to the
laboratory facilities in a sterile container containing
saline buffer, in a hermetically sealed sterile container,
and processed within a period up to 48 h. Identical cord
tissue sections were digested, using a precise ratio be-
tween tissue mass, tissue digestion enzyme activity units,
digestion solution volume and void volume using col-
lagenase (Sigma-Aldrich, Co.). The procedure includes
three recovery phases in order to avoid non-conformities
related to percentage cell recovery. In the first cell recov-
ery phase, cells dissociated from the tissue are recovered
by a static horizontal incubation. The remaining cells are
incubated in a static monolayer culture using basal
medium [α-MEM, 1 g/L glucose (Sigma-Aldrich, Co.);
2.2 g/L sodium bicarbonate (Sigma-Aldrich, Co.), supple-
mented with 2 mM L-glutamine (Sigma-Aldrich, Co)
and 20% FBS (Gibco, Life Technologies)], at 37°C in 7%
CO2 humidified atmosphere, with medium change every
72 h until they reached confluence. Confluent cultures
were cryopreserved in 10% dimethylsulphoxide stock
solution (DMSO; Sigma-Aldrich, Co.) and FBS, using
control rate temperature decrease.UCX® expansion and characterization
Human cryopreserved UCX® cells were thawed and
expanded to P5 in complete culture medium (α-MEM, 20%
FBS, 1 g/L glucose, 2 mM glutamine) with medium change
every 72 h. Cells were characterized by their capacity to
adhere to plastic in standard MSCs culture conditions.
Surface marker expression was analyzed by flow cytometry
using a Gallios imaging flow cytometer (Beckman Coulter
Inc., CA, USA). The antibodies used and their conjugates
were: anti-human CD105 - PE (eBioscience) anti-human
CD73 – APC, anti-human CD90 – PE, anti-human CD14 -
PerCp/Cy5.5, anti-human CD45 – PerCp/Cy5.5, anti-
human CD34 – FITC, anti-human CD19 pacific blue,
anti-human HLA-DR Pacific blue, isotype Pacific blue
IgG1, isotype Pacific blue IgG2a), isotype IgG1k PerCp/
Cy5.5 ), isotype IgG2a PerCp/Cy5.5, isotype IgG1k - PE,
isotype IgG1k APC and isotype IgG1k FITC (all from
Biolegend, Inc.). For flow cytometry studies cells were
incubated for 1 h at 4°C with the antibodies in 2% (w/v)
bovine serum albumin solution (Sigma-Aldrich, Co.),
centrifuged and washed with phosphate-buffered saline
(Sigma-Aldrich, Co.). To induce adipogenic differenti-
ation, cultured cells were incubated in adipogenic differen-
tiation medium, for 3 days, consisting of α-MEM
supplemented with 20% FBS, 2 mM L-glutamine, 10 μg/
mL insulin (Sigma-Aldrich, Co.), 200 μM indomethacin
(Sigma-Aldrich, Co.), 0.5 mM isobutylmetylxantine
(Sigma-Aldrich, Co.), and 1 μM dexamethasone (Sigma-
Aldrich, Co.); and subsequently 1 day in adipogenic main-
tenance medium, consisting of α-MEM supplemented
with 20% FBS, 2 mM L-glutamine and 10 μg/mL insulin.
Medium replacement cycles were repeated during 21 days
after which histochemical staining was performed. For
chondrogenic differentiation, cells were grown in sus-
pension as pellets, incubated with chondrogenic differ-
entiation medium consisting on DMEM-LG (Sigma-
Aldrich, Co.), 1% FBS, 2 mM L-glutamine, 6.25 μg/mL in-
sulin (Sigma-Aldrich, Co.), 10 ng/mL TGF-β1 (Tebu-bio),
and 50 μM ascorbate-2-phosphate (Sigma-Aldrich, Co.).
The medium was replaced every 3 days during 21 days
and histochemical staining was performed. Finally, to in-
duce osteogenic differentiation, cells were incubated in
osteogenic differentiation medium [α-MEM, 10% FBS,
1 g/L glucose, 2 mM glutamine, 10 mM β-glycerol phos-
phate, 50 μg/mL ascorbate-2-phosphate and 100 nM
dexamethasone (all from Sigma-Aldrich, Co.)]. The
medium was replaced every 3 days during 21 days and
histochemical staining was performed. In adipogenic and
osteogenic differentiation protocols, cells were washed
and fixed with paraformaldehyde 4% for 20 min and
stained with oil red O and alkaline phosphatase, respect-
ively. For chondrogenic differentiation, cells were also
fixed in paraformaldehyde 4%, dried and cut into sections
and finally stained with alcian blue. The presence of
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phase contrast (Leica, DMIL HC).
Mixed lymphocyte reaction (MLR)
Peripheral blood samples were obtained from healthy
volunteers of both sexes after informed consent. The MLR
was performed in 96-well microtiter plates using RPMI
(Gibco), and 5% human serum obtained from the specific
donor. Peripheral blood monocytes (PBMCs) were
obtained from two different donors and cultured at 2 x 105
cells per well. Stimulator cells were irradiated with 50 Gy
(Gammacell ELAN 3000, Best Theratronics) prior to
addition to the culture at 20,000 cells per well. Quadrupli-
cate cultures were performed for each condition. Cultures
were incubated at 37°C in 5% CO2 for 6 days, pulsed with
[3H]thymidine (1 microCi per well, Amersham Biosciences,
Piscataway) for 16 hours, and the cells were harvested onto
filter mats using a Tomtec 96-well cell harvester (Perkin
Elmer). Radioactivity incorporated into the dividing cells
was determined using a scintillation counter (Microbeta
Trilux Scintillation and Luminescence Counter 145 LSC,
Perkin Elmer). BM-MSCs used as controls in this and
following experiments were purchased from Innoprot
(Cat. P10576) and grown according to supplier's up to P5.
Cell sorting of CD3+CD4+CD25- T-cells and cultures for
conversion into CD4+CD25+Foxp3+ Tregs
Peripheral blood from healthy volunteers was collected in
heparin, diluted 1:1 (v/v) with PBS and mixed with half the
volume of Histopaque®-1077 (Sigma). Cells were collected
from the Ficoll gradient after centrifugation at 720 g for 30’
at RT, washed with PBS containing 2% FCS and then
stained with mAbs against human CD3, CD4 and CD25
(Ebioscience) for cell sorting. The purified CD3+CD4
+CD25- T-cells were cultured in plate-bound αhuCD3
(2.5 μg/ml, Ebioscience) in 96-well flat-bottom plates in
the following conditions. Briefly, 1x105 purified T-cells/well
were cultured in the presence of αhuCD28 (2 μg/ml,
Ebioscience), huIL-2 (20 U/ml, Peprotech), and TGF-β
(10 ng/ml, R&D Systems) or the indicated cell lines (irra-
diated as described), in replacement of TGF-β, in a ratio of
1:1 to the T-cells. All conditions were performed in tripli-
cate wells. After 5 days in culture at 37°C with 5% CO2,
cells were stained with mAbs against human CD3, CD4
and CD25 (Ebioscience) and then stained for huFoxp3 as
described by the manufacturer (Ebioscience). The analysis
was performed on the converted CD4+Foxp3+ regulatory
T-cells.
Acute carragenan-induced arthritic (CarrIA) inflammatory
model
Carrageenan and indomethacin were purchased from
Sigma Aldrich (St. Louis, MO, USA). At least 6 male
Wistar rats, minimum 7 to 8 weeks-old, were used perexperimental group. Paw edema was induced by intrader-
mal injection of 0.1 mL of a 1% carrageenan saline solu-
tion into the subplantar area of the right hind paw [24].
The evaluation of the paw edema was monitored by
changes of the volume of right and left paws by a water
displacement method, using a plethysmometer (Ugo
Basile, Comerio, Italy). The paws were immersed in the
measurement cell up to the hair line of the ankle to deter-
mine the immersed organ volume in mL. Measurements
were made immediately before the injection of carra-
geenan and thereafter at 2-hr intervals for 6 hr. Edema
was expressed as the increase in paw volume (milliliters)
after carrageenan injection relative to the pre-injection
value for each animal. Sub-cutaneous indomethacin
(30 mg/kg) administration was performed 30 min before
carrageenan injection. Cells at a concentration of 1.7 x106
in a total volume of 0.1 mL or vehicle PBS (0.1 mL) were
administered by intra articular (i.a.) injection in the right
paw, 30 min before carrageenan injection.
Chronic adjuvant-induced arthritis (AIA) model
Mycobacterium butyricum (killed and dried) and incom-
plete Freund´s Adjuvant were purchased from Difco
Laboratoires, Detroit, Michigan, USA. All other chemi-
cals were of analytical grade. Six to 8 male Wistar rats
aged four months were used. As a rule, inflammation
was induced by a single intra-dermal injection of
0.10 mL of a 10 mg/mL suspension of M. butyricum in
Incomplete Freund's Adjuvant, homogenized by ultra-
sound into the sub-plantar area of the right hind paws
[25,26]. Before treatment, animals were randomly allo-
cated to 6 different treatment groups. One group of
induced animals remained untreated, being further re-
ferred as Control Untreated. Other 2 groups of induced
animals received PBS by intra-articular (i.a.) or intra-
peritoneal (i.p.) routes of administration, respectively;
being further referred as Sham groups. These groups
were kept under the same conditions as treated animals.
A total of five i.p. administrations (dose: 1.000x106 cells/
injection) were performed every day, from day 13 to 17.
In turn, three i.a. administrations (low dose: 0.425x106
cells/injection; high dose: 1.700x106 cells/injection) were
performed every other day, for five days, from day 13 to
17. The experiment lasted for 55 days. The therapeutic
effect of UCX® cells was evaluated by physical changes
in several parameters: body weight, ankle circumference
and volume of right and left paws. Animals were scored
for clinical arthritis as previously described, with some
modifications [27]. At pre-selected times animals were
blindly graded based on the sum of the following grades:
0 = normal; 1 = for each inflamed paw; 1 = tail lesion; 1 =
joint rigidity or deformity; 1 = wounded paw; 1 = infected
paw; 1 = necrotic paw. The sum of the parameters was
calculated as an arthritic index with a maximum possible
Figure 1 UCX® cell characterization. Isolated UCX® cells presented (A) a fusiform, fibroblast-like morphology in culture. Results from Flow
Cytometry analysis of cell surface markers presented in (B) histograms (UCX® cells in dark grey and isotype control in light grey) and (C) column
bars. The values are represented as the mean ± SEM (n = 8).
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graphically recorded and compared to naive animals.
Treatment was initiated after the onset of the disease
(day 13), when arthritis had become established (AI
score of 4).
Results
UCX® cell characterization: cell culture and flow
cytometry analysis of cell
Surface markers
UCX® cells were expanded to P5 (12.3 ± 2.5 generations,
n = 8) where the culture appeared homogeneous andcells presented their typical fusiform, fibroblast-like,
morphology (Figure 1A). As expected for MSC-type
stromal cells, flow cytometry analysis showed that over
98% of the cells in the population were consistently posi-
tive for the cell surface markers CD44, CD73, CD90 and
CD105 and less than 2% positive for CD14, CD19,
CD31, CD34, CD45 and HLA-DR (Figure 1B and 1C).
UCX® cell characterization: Tri-lineage terminal differentiation
UCX® cells were expanded to P5 and incubated with
specific differentiation media as described in the meth-
ods. Results showed that UCX® cells have the capacity
Figure 2 Tri-lineage differentiation potential of UCX® cells.
Multi-lineage differentiation potential of UCX® cells were
qualitatively analyzed by histological staining methods. Adipogenic
differentiation was assessed with Oil Red O staining both in (A)
control and (B) differentiated samples; chondrogenic differentiation
with Alcian Blue staining in (C) control and (D) differentiated
samples; and osteogenic differentiation with Alkaline Phosphatase
staining in (E) control and (D) differentiated samples. The photos are
representative of one out of eight umbilical cords tested.
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cytes and osteoblasts (Figure 2A-F). Control samples on
the left column are cell cultures undergoing same cul-
ture conditions and specific staining reactions but with-
out addition of differentiation factors. For chondrogenic
differentiation, the natural tendency for UCX® cells to
form three-dimensional aggregates has become notice-
able, even without the addition of differentiaion factors























Figure 3 UCX® cells suppress T-cell proliferation. In a MLR, suppression
MSCs and control non-MSCs (Molt-4) following activation of PBMCs from tw
presented as mean ± SEM (n = 4) and statistically significant differences areterminal chondrogenic differentiation are consistently
larger, more regularly shaped, and strongly stain positive
for alcian blue (Figure 2D).UCX® cells have the capacity to suppress T-cell proliferation
and to induce treg conversion
Wharton’s jelly-derived MSCs have been shown to be able
to be safely used in allogeneic applications due to both
their lack of immunogenicity when compared to other
MSCs, and their marked capacity for localized immuno-
suppression. In order to evaluate the capacity of UCX®
cells to modulate T-cell activation, peripheral blood mono-
nuclear cells (PBMCs) from 2 different donors were stimu-
lated with anti-CD3, anti-CD28 and IL-2 while co-cultured
with irradiated UCX® cells, bone marrow-derived mesen-
chymal stem cells (BM-MSCs) and tumor cells belonging
to an acute lymphoblastic leukemia adult cell line (Molt4)
as non-MSC control. Results showed that in two different
donors, both MSC-type cells have an immunosuppressive
effect when compared to Molt-4 (Figure 3). Moreover,
UCX® cells were able to inhibit T-cell proliferation more
significantly than BM-MSCs, suggesting that these cells
are more immunosuppressive than BM-MSCs.
The capacity of UCX® cells to take a multi modal
approach to immune regulation, through induction of
Tregs was also evaluated. Tregs are a sub-set of naive
CD4+CD25+ T-cells that express the Foxp3 transcription
factor and become regulatory in the periphery in response
to a variety of signals, including antigen exposure in the
presence of immunosuppressive cytokines such as TGF-β
[28]. Previous studies have demonstrated that not all
CD4+CD25+ cells concomitantly expressed Foxp3, while
only very few Foxp3+ cells resided in the CD25- popula-
tion [16,29]. However, Foxp3 remains the best marker to
identify regulatory T-cell populations [30]. Therefore, in
this study we assessed Foxp3 expression in FACS-sorted




of T-cell proliferation was analyzed in the presence of UCX® cells, BM-
o different donors with anti-CD3, anti-CD28 and IL-2. Data is
indicated with asterisks (non-parametric test Mann Whitney, *P < 0.05).
Figure 4 UCX cells induce T-cell conversion into Treg cells. FACS-sorted CD3+ CD4+ CD25- T-cells were activated with anti-CD3, anti-CD28
and IL-2 alone (A) and with the addition of TGF-β (B). The effect of irradiated UCX® cells (C) and BM-MSCs (D) in T-cell conversion was analyzed
in cultures without exogenous TGF-β by flow cytometry analysis of CD25 and Foxp3 expression.
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in inducing the conversion of Treg cells we used an
in vitro co-culture system where sorted polyclonal popu-
lations of CD4+CD25- T-cells from human donors were
activated in the presence or absence of UCX® cells. It
has been shown that immunosuppressive reagents can
induce Treg cells independently of the addition of
exogenous TGF-β to the cultures [31]. The therapeutic
induction of Foxp3+ Treg cells can then protect from
inflammatory pathology such as arthritis or neuro-
inflammation [32,33].
We found, as expected, that T-cell activation with
anti-CD3, anti-CD28, and IL-2 in the absence of exogen-
ous TGF-β did not lead to induction of CD4+Foxp3+
cells (Figure 4A - negative control). On the contrary, we
confirmed that addition of TGF-β to the culture resulted
in considerable Treg conversion (positive control,
Figure 4B). In the experimental group we found that the
presence of UCX® cells resulted in significant induction
of Treg conversion of over 18% of the CD4+ cell popula-
tion (Figure 4C). Although not as efficient as UCX®
cells, BM-MSCs also promoted conversion of Tregs
(approx. 16%, Figure 4D). Taken together, these data
establish the ability of UCX® cells to induce Foxp3+Treg cells, as well as a potent effect in suppressing
T-cell activation.
UCX® cells have the capacity to reduce inflammation in vivo
in an acute carrageenan-induced arthritis (CarrIA) model
In order to assess if UCX® cell immunosuppression
properties could result in arthritic anti-inflammatory
activity in vivo, cells were administered in an acute
carrageenan-induced arthritis (CarrIA) footpad edema
model. The CarrIA is a model for acute inflammation and
provides a rapid assessment of the anti-inflammatory
effect of a certain compound. In this study, different
groups (n = 12 for Sham and UCX®, n = 6 for dead UCX®
and BM-MSCs) of 7 to 8 week-old Wistar rats were trea-
ted either with PBS vehicle (Sham control), live viable
UCX® cells (dose 1.7x106 cells), dead non-viable human
UCX® cells (dose 1.7 x106 cells), and human BM-MSCs
(dose 1.7x106 cells) 1 hour prior to challenge with λ-
carrageenan in the right hind footpad. Edema was
measured as the increase in paw volume (milliliters) after
carrageenan injection (relative to the pre-injection
volume). Results showed that in vehicle-treated paws
(sham control) footpad volume peaked at time 6 h and
regressed back to near baseline levels 24 h after








































Figure 5 UCX® cells suppress carragenan-induced arthritis. UCX® arthritic anti-inflammatory activity in vivo was assessed by measuring the
(A) paw volume at several time points both before and after carrageenan induction relative to the pre-injection volume and (B) paw volume at
maximum peak time - 6 h, relative to the pre-injection volume. Data is presented as mean ± SEM and statistically significant differences are
indicated with asterisks (non-parametric test Mann Whitney, *P < 0.05).
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that non-viable UCX® cells induced a slightly increased
inflammatory response up to 6 h when compared to the
Sham control. This inflammatory response was not
observed with either viable BM-MSCs or UCX® cells.
Nevertheless, while the injection with BM-MSCs caused a
similar effect as Sham control, injection of UCX® cells
strongly attenuated paw inflammation, clearly reverting
edema formation in a cell-specific fashion. In agreement
with the immunosuppression activity observed in vitro
(Figures 3 and 4), Figure 5B showed a statistically signifi-
cant reduction (over 30%) in hind paw inflammation at
time 6 h in UCX® -treated animals when compared to
Sham control and BM-MSCs-treated animals. In addition,
the anti-inflammatory effect of UCX® cells observed
in vivo was dependent on cell viability, as seen by the loss
of activity observed when using non-viable UCX® cells.
These results showed that in addition to the observedimmunosuppressive activity seen in vitro, UCX® cells have
an anti-inflammatory effect in vivo.
UCX® treatment prevented the development of arthritic
inflammation manifestations in a chronic adjuvant-induced
arthritis (AIA) model
The immunoregulatory effects of UCX® on T-cells, as well
as the anti-inflammatory activity observed in the xenogen-
eic CarrIA model prompted to investigate the potential
therapeutic effects of UCX® cells in the chronic AIA
model, an arthritis model that shares many clinical and
immunological features with RA. Both local (intra- articu-
lar- i.a.) and systemic (intra-peritoneal – i.p.) routes of ad-
ministration were tested and, in the case of i.a., a dose
effect for UCX® cells was also evaluated. The treatment
schedule and UCX® dosage are shown in Figure 6. Arth-
ritis was induced in the sub-plantar area of right hind
paws and the onset of arthritic manifestations was
Figure 6 Treatment schedule and UCX® dosage for the chronic adjuvant induced arthritis (AIA) model. In the AIA experiment, animals
were randomly allocated to 6 different treatment groups. One group of induced animals remained untreated, being referred as Control
untreated. Other 2 groups of induced animals received PBS by intra articular (i.a.) or intra peritoneal (i.p.) routes, respectively, being referred as
Sham groups. A total of five i.p. administrations (dose: 1.000x106 cells/injection) were performed every day, from day 13 to 17. In turn, three i.a.
administrations (either low dose: 0.425x106 cells/injection; or high dose: 1.7x106 cells/injection) were performed every other day, for five days,
from day 13 to 17 after arthritis induction. Arrows indicate injection days. The experiment lasted for 55 days.
Figure 7 Differential local effects of (i.p.) and (i.a.) UCX® cell administration in the AIA model. Graphical representations of % variation
analysis of (A,B) paw volume regression related to naive animals, and (C, D) paw circumference regression related to naive animals, during the
time scoped by the AIA model experiment, both in (A,C) systemic and (B, D) local administration of UCX® cells and Sham controls. Data is
presented as mean ± SEM (n = 8).
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Figure 8 Local and systemic delivery of UCX® cells prevent global arthritic manifestations in the AIA model. Graphical representations of
(A, C) AI variation during the time scoped by the AIA model experiment. Animals were scored at pre-selected times based on the sum of the
following grades: 0 = normal paw; 1 = for each inflamed paw; 1 = tail lesion; 1 = joint rigidity or deformity; 1 = wounded paw; 1 = infected paw; 1 =
necrotic paw. The sum of the parameters was calculated to a maximum AI of 9. Data is presented as mean ± SEM (n = 8). The evolution of clinical
signs was photographically recorded (B, D) and compared to both normal and Sham-treated animals. Photos are representative of 8 animals.
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score of 4, see methods section).
Figure 7 (A-D) depicts % variations (regression) related
to naive animals in both, volume of posterior right hind
paw and ankle circumference, for systemic (i.p.) and
local (i.a.) administration groups. In all experimental
groups, animals typically lost near to 20% body weight
during the acute phase of the disease, between days 13
and 20 after induction (results not shown). Body weight
recovery between days 20 and 55 was accompanied by
regression of hind paw inflammation in all experimental
groups. However, UCX® i.a. administration proved to be
highly effective in ameliorating local inflammatory sig-
nals when compared to UCX® i.p. administration. While
UCX® i.p. administration has shown no improvements
in local inflammation, when compared to the Sham
control (Figure 7A and 7C), UCX® i.a. administration
promoted a significantly faster regression of both hind
paw volume and hind paw circumference, from days 20
to 55 (Figure 7B and 7D). The promotion of hind paw
volume regression caused by UCX® cells was shown to
be dose dependent, with the highest UCX® cell dose
reaching an average of nearly 80% volume recovery at
day 55 (Figure 7B).When all local and systemic parameters were taken
together, as a measure of the arthritic index (AI), the
positive effect of UCX® treatment became clear. As it
can be seen in Figure 8A and 8C the severity of AIA was
rapidly attenuated overtime in UCX®-treated mice, as
compared with both control untreated and vehicle
(Sham) treated groups. As observed in Figure 8A, the
Sham group reached a maximum AI score of 7.6 (day 38)
while i.p. UCX® -treated animals reached a maximum of 5
after arthritis induction (day 21). In the case of local treat-
ment (Figure 8C), the Sham group reached a maximum
AI of 6 at day 32 after induction and significant lower
values were obtained for treated groups, in a dose-
dependent fashion. The Sham group presented a decrease
in AI values following the same trend as treated groups
but with higher severity index (Figure 8C). This can pos-
sibly be interpreted as either a local wash-away effect,
reducing the infection locally, or a decompressing effect
due to i.a. injection that released pus, thereby reducing
hind paw volume. Just like the promotion of volume and
paw circumference regression before (Figure 7D and 7F),
the reduction of AI scores during the follow up of i.a.
administration was shown to be UCX® dose-dependent
(Figure 8C). The AI scores were representative of the
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croscopic observations. Unlike UCX® treated animals,
control untreated and Sham group animals have evolved
from an hind-paw inflammation stage to the presence of
articular deformities, low mobility, tail and paw lesions by
day 38; and ultimately developed clear signs of paw necro-
sis and irreversible joint rigidity between days 48 and 55
(Figure 8B and 8D). In turn, animals in both i.p. and i.a.
UCX®-treated groups have reached a mild articular
inflammation stage, with subtle-to-mild systemic signs of
disease up to day 38. From day 38 to 55, animals treated
systemically, through an i.p. mode of administration, have
recovered in part the local arthritic symptom, suggesting
that UCX® administered systemically affect the clinical
course of AIA. In turn, animals treated locally, through an
i.a. mode of administration, with a high UCX® dose,
presented apparent full recovery of both local and sys-
temic manifestations, as well as local motor hindrance
(Figure 8B and 8D). The results suggest that UCX® cells
were successful in protecting against the development of
more severe arthritic manifestations, from a period with
already observable manifestations, day 13 (AI of 4) to day
38 after induction Additional to this protective effect, both
i.p. and i.a.-administered UCX® cells were able to promote
regression of arthritic signs, significantly reducing the AI
parameters. UCX® cells can thus be an effective and
promising new approach for treating both local and sys-
temic arthritis.
Discussion
The present study shows that human UCX® cells are a
homogenous population of stem cells that comply with
the current definition of mesenchymal stromal cell (MSC)
as established by the International Society for Cellular
Therapy (ISCT) [34] namely, cells adhere to a plastic sur-
face, at least 95% of UCX® cells in the population are con-
sistently positive for the cell surface markers CD44, CD73,
CD90 and CD105 and less than 2% positive for CD14,
CD19, CD31, CD34, CD45 and HLA-DR, and cells are
capable of undergoing tri-lineage differentiation into adi-
pocytes, chondrocytes and osteoblasts. More importantly,
UCX® cells have the capacity to inhibit human T-cell pro-
liferation, and concomitantly induce the conversion of
T-cells to the Treg sub-type of regulatory cells. Our results
showed that such capacity is more evident in UCX® cells
than in BM-MSCs, sometimes considered the gold stand-
ard for MSC therapy applications.
Our results also showed that, in a xenogeneic setting,
human UCX® cell immunosuppression properties can
result in arthritic anti-inflammatory activity in vivo, both
in acute and chronic arthritis animal models. UCX® cells
administered in a rat CarrIA model strongly attenuated
hind paw inflammation, protecting against acute edema
formation in a cell-specific fashion. Furthermore, UCX®action in vivo was dependent on cell viability. The anti-
inflammatory effect was not observed when using human
BM-MSCs in the same acute model, in accordance to the
lower immunosuppressive capacity observed in vitro. The
differences in anti-inflammatory behavior between UCX®
cells and BM-MSCs, as seen in a CarrIA model, agree with
previous studies where UC-MSCs have proven effective in
treating collagen-induced arthritis in mice [16], while BM-
MSCs have been shown to be ineffective in AIA rats [35].
These different observations also show that MSCs from
different tissue sources should not be treated as equal in
terms of their immunosuppressive and anti-inflammatory
activities and should therefore be discussed and evaluated
as separate treatment strategies.
In fact, a comparative study between BM-MSCs and
Wharton’s Jelly-derived UC-MSCs, primed with key pro-
inflammatory cytokines IFN-γ and TNF-α, showed that
the extent of immunosuppression was more accentuated
with UC-MSCs than with BM-MSCs in both cases [14].
Furthermore, priming BM-MSCs with IFNγ enhanced
suppression of mitogen-driven lymphocyte proliferation
only, whereas IFN-γ primed UC-MSCs were better sup-
pressors in MLRs, in agreement with our observations
using UCX® cells. Additionally, PHA-stimulated lympho-
cytes in co-cultures of primed/unprimed UC-MSCs and
BM-MSCs showed that UC-MSCs resulted in an early
activation of a negative co-stimulatory molecule, CTLA4,
which was not evident with BM-MSCs [14]. In summary,
different expression patterns indicated that UC-MSCs
were less immunogenic, more immunosuppressive and
more inflammatory than BM-MSCs [14].
More recently, the observations described above have
been further consubstantiated. High throughput gene
expression analysis using microarrays (GeneShip® from
Affymetrix) have shown that UCX® cells express signifi-
cantly higher levels of IL-8, IL1β, LIF and TGFβ when
compared with BM-MSCs. The receptors for pro-
inflammatory cytokines such as IFN-γ, TNFα and IL-1β
were also found substantially expressed in UCX® cells,
which is consistent with the reported ability of these cells
to home to inflammation sites and become immunosup-
pressive in response to inflammatory signals (results to be
published elsewhere). The expression of LIF and TGF-β
are particularly relevant for this study since both have been
directly implicated in Treg induction [36,37].
Finally, the combined immunosuppressive and anti-
inflammatory capabilities of human UCX® cells were suc-
cessfully applied to the treatment of AIA in vivo. treated
animals, through an i.a. mode of administration, presented
full recovery of both local and systemic AIA signs, as well
as local motor hindrance. Overall, the results suggest that
UCX® cells have been successful in protecting against the
development of more severe manifestations of arthritis,
from a period with already observable manifestations at
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controls and untreated animals developed clearly more
severe conditions. Additional to this protective effect, both
i.p. and i.a.- administered UCX® cells were able to pro-
mote regression of arthritic manifestations, reducing all
measurable and observable IA parameters. To our know-
ledge, this study presents the first evidence of successful
treatment of chronic adjuvant-induced arthritis (AIA)
where MSC-type cells have been administered after the
appearance of clear AIA manifestations.
Human UC-MSCs have been shown previously to sup-
press the various inflammatory effects of FLSs and T-cells
of RA in vitro, and to attenuate the development of
collagen-induced arthritis (CIA) in mice. In addition, the
immunosuppressive activity of UC-MSCs was prolonged
by the participation of Tregs [16]. Tregs modulate a var-
iety of immune functions from initial T-cell and B-cell ac-
tivation to effector function in the target tissue, and
appear to play a critical role in the maintenance of self-
immune tolerance in RA [28,38]. Some authors consider
that CD4+CD25+ cells in PBMCs contain a mixture of
both thymic natural Tregs (nTregs) and periphery induced
Tregs (iTregs). The generation of iTregs is dependent
upon the presence of both TGF-β and TGF-β receptor
signals. Furthermore, iTregs are known to be superior to
nTregs in ameliorating established CIA, as well as other
types of ongoing autoimmunities [39]. We would like to
propose that the use of UCX® cells is an effective and
promising new approach for treating autoimmune-derived
inflammatory arthritis symptoms by a mechanism involv-
ing homing to inflammation sites and immunosuppression
via a two-way pathway: 1- repression of T-cell prolifera-
tion and 2- TGF-β-dependent paracrine promotion of
iTreg conversion. The beneficial effects can be extended
to the systemic nature of autoimmune inflammatory arth-
ritis disorders, such as RA.
Conclusion
The present study has provided strong evidence that
UCX® cells are strong candidates to become an Advanced
Therapy Medicinal Product (ATMP) for the treatment of
inflammatory arthritis in the near future.
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